Insmed (NASDAQ:INSM) had its price target raised by analysts at Morgan Stanley from $157.00 to $162.00. They now have an "equal weight" rating on the stock.
What Insmed (INSM)'s Upcoming TPIP Data and New Analyst Coverage Mean For Shareholders [Yahoo! Finance]
Insmed TPIP Data At PVRI 2026 Tests Pulmonary Arterial Hypertension Ambitions [Yahoo! Finance]
Insmed (NASDAQ:INSM) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress